People with hereditary angioedema (HAE) who have normal C1-inhibitor (C1-INH)Â levels and activity appear to have more active disease and…
Margarida Maia, PhD
Margarida is a biochemist (University of Porto, Portugal) with a PhD in biomedical sciences (VIB and KULeuven, Belgium). Her main interest is science communication. She is also passionate about design and the dialogue between art and science.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Margarida Maia, PhD
Transitioning from other prophylactic, or preventive, treatments, to Orladeyo (berotralstat) or Takhzyro (lanadelumab) can take some time and…
Switching to Orladeyo (berotralstat) may help reduce the frequency and duration of swelling attacks in people with hereditary…
An immediate-release capsule of deucrictibant that’s being developed by Pharvaris continues to show promise as an on-demand and preventive…
A young woman who developed angioedema of the small bowel after taking two different angiotensin-converting enzyme (ACE) inhibitors showed…
A man in Japan may have developed acquired angioedema as a late complication of graft-versus-host disease, which occurred when…
People with hereditary angioedema (HAE) who were new to Orladeyo (berotralstat) treatment saw rapid reductions in the number…
Sebetralstat, an oral small molecule being developed by KalVista Pharmaceuticals as an on-demand treatment for hereditary angioedema (HAE),…
Three genetic regions were found to be associated with the risk of developing angioedema as a…
People with hereditary angioedema (HAE) who switched from long-term androgen treatment to BioCryst Pharmaceuticals’ Orladeyo (berotralstat) saw a…